PUBLISHER: The Business Research Company | PRODUCT CODE: 1409482
PUBLISHER: The Business Research Company | PRODUCT CODE: 1409482
“Hepatitis Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hepatitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hepatitis therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hepatitis therapeutics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Hepatitis denotes inflammation of the liver caused by various viruses and non-viral factors. Hepatitis therapeutics encompasses medications designed to treat all forms of hepatitis, with immune modulators and oral antivirals being the primary drugs employed.
The principal disease types addressed through hepatitis therapeutics include hepatitis A, hepatitis B, hepatitis C, and other related conditions. Hepatitis A involves liver inflammation that can manifest as mild to severe illness. These therapeutics are categorized based on drug class into oral antivirals and immune modulators, with distribution channels extending to hospital pharmacies, drug stores, retail pharmacies, and online providers.
The hepatitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides hepatitis therapeutics optical components market statistics, including hepatitis therapeutics optical components industry global market size, regional shares, competitors with a hepatitis therapeutics optical components market share, detailed hepatitis therapeutics optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics optical components industry. This hepatitis therapeutics optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.35 billion in 2023 to $18.89 billion in 2024 at a compound annual growth rate (CAGR) of 3.0%. The growth observed during the historical period can be ascribed to factors such as the development of vaccines, the availability of antiviral medications, public health initiatives, increased research funding, and the emergence of new therapies.
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $21.79 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The anticipated growth in the forecast period can be attributed to ongoing research and development, global health endeavors, changes in patient care approaches, government initiatives, and increasing awareness of diseases. Key trends expected in the forecast period encompass patient advocacy and support, continuous monitoring and follow-up, efforts towards healthcare equity, the adoption of telemedicine and remote care, and a specific focus on the elimination of hepatitis C.
The hepatitis therapeutic market is anticipated to experience growth due to the global rise in hepatitis infections. The surge in hepatitis cases can be attributed to factors such as inadequate access to healthcare and vaccinations, increased intravenous drug use, unsafe blood transfusion practices, and suboptimal sanitation and hygiene conditions in certain regions. As of April 2022, the World Health Organization (WHO) reported at least 169 cases of acute hepatitis of unknown origin in 11 nations, with an estimated 350 million individuals worldwide affected by viral hepatitis B or C. However, for the majority of affected individuals, testing and treatment remain inaccessible. Consequently, the hepatitis therapeutics market is expanding in response to the escalating prevalence of hepatitis infections.
The growth of the hepatitis therapeutic market is expected to be driven by the increasing number of clinical trials. Clinical trials, which involve evaluating new treatments and interventions in human participants, play a pivotal role in the development of hepatitis therapeutics. These trials provide a rigorous and ethical framework to assess the safety and efficacy of potential treatments, ensuring that patients have access to the most effective therapies available. According to Pharma Intelligence in June 2022, the total number of completed clinical trials witnessed an 8.8% increase, reaching 4,109 trials in 2021 compared to 3,777 trials in 2020. Therefore, the surge in clinical trials is a significant factor contributing to the growth of the hepatitis therapeutics market.
A key trend in the hepatitis therapeutics market is the emergence of product innovations. Major companies in the market are actively involved in developing new products to maintain their market position. In November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company, obtained FDA approval for Vemlidy (tenofovir alafenamide) to treat pediatric patients with chronic hepatitis B virus infection. Vemlidy, a targeted prodrug of tenofovir, was initially approved in 2016 as a once-daily treatment for chronic hepatitis B virus infection and compensated liver disease in adults. It is recognized as a preferred or first-line treatment according to recommendations from the American Liver Foundation.
Strategic agreements have become a focal point for major companies operating in the hepatitis therapeutics market, aimed at gaining a competitive edge. In October 2023, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced an exclusive licensing agreement for JNJ-3989, an investigational subcutaneous RNA interference therapeutic designed for treating chronic hepatitis B (CHB). JNJ-3989 is an innovative RNA interference therapeutic targeting the hepatitis B virus (HBV) X protein, which is crucial for HBV replication and persistence.
In March 2021, Gilead Sciences Inc., a US-based biopharmaceutical company, acquired MYR GmbH for $1.5 billion. This acquisition provided Gilead Sciences Inc. with Hepcludex (bulevirtide), conditionally approved by the European Medicines Agency for treating chronic hepatitis delta virus (HDV) in adults with compensated liver disease. MYR GmbH, a Germany-based biotechnology company, focused on developing and commercializing therapeutics for chronic B and D infections.
Major companies operating in the hepatitis therapeutics market report are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Mylan NV, Pfizer Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Biocon Biopharmaceuticals Pvt. Ltd., Zealand Pharma A/S, Zenyaku Kogyo Co. Ltd., Zosano Pharma Corporation .
North America was the largest region in the hepatitis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.